Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.

@article{Festuccia2017HematopoieticCT,
  title={Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.},
  author={Moreno Festuccia and Kelsey K Baker and Theodore A Gooley and Brenda M Sandmaier and H Joachim Deeg and Bart L Scott},
  journal={Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation},
  year={2017},
  volume={23 9},
  pages={1509-1514}
}
The prognosis of patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent (HMA) therapy is poor. Allogeneic hematopoietic cell transplantation (HCT) can be effective in curing patients who have failed therapy with HMA. However, published results have not addressed the outcomes with HCT in this setting. We identified 125 MDS patients who had been treated with HMA and underwent subsequent HCT. Among these, 68 were considered HMA failures and 57 responders. Failure was… CONTINUE READING